

# An Elementary School Outbreak of Varicella Attributed to Vaccine Failure

B. Lee<sup>1</sup>, S. Feaver<sup>1</sup>, C. Miller<sup>1</sup>, C. Hedberg<sup>2</sup>, and K. Ehresmann<sup>1</sup> <sup>1</sup> Minnesota Department of Health, Minneapolis, MN; <sup>2</sup> University of Minnesota School of Public Health, Minneapolis, MN Contact: Brian R. Lee Minnesota Department of Health 717 SE Delaware Street, Minneapolis, MN 55414 brian.lee@health.state.mn.us Phone: 612-676-5414 FAX: 612-676-5743

0.0089

0.005b

0.004°

<0.002b

1.8 (1.2 - 2.7)

Table 3. Characteristics of Illness among Cases Without Prior History of

Varicella, By Vaccination Status

### ABSTRACT

Background: Since U.S. licensure, studies have shown the varicella vaccine's overall effectiveness to range from 44-100%, with substantial protection against moderate and severe varicella; however, break through disease has been documented in up to 56% of vaccinated individuals.

Methods: A varicella outbreak occurred in a Minnesota school with 319 students. Phone surveys were conducted with students' parents. Information was collected on students with recent varicella infections including onset date, rash characteristics, duration, and underlying medical conditions.

Results: Fifty-four cases occurred following a primary, breakthrough case. Twenty-nine (53%) cases were vaccinated. Unvaccinated students had an increased risk of moderate varicella compared to vaccinated students (RR 44:95% CL 2.2to 9.1:n<0.001). The vaccine was 56% effective at preventing any varicella and 90% effective against moderate illness. Students vaccinated five or more years prior to the outbreak had a greater risk of breakthrough varicella compared to those vaccinated within four years (RR 2.6.95% CL 1.3

Conclusions: Vaccinated students presented with milder varicella symptoms than unvaccinated students Individuals with breakthrough disease can be highly infectious. Time since varicella vaccination was associated with illness. Despite 29 breakthrough cases, the varicella vaccine conferred a high degree of protection against moderate illness

# BACKGROUND: VARICELLA-ZOSTER

- · Before vaccine licensure in the United States, varicella disease accounted for an estimated 4 million cases, 11,000 hospitalizations, and 100 deaths
- Median incubation period for varicella illness is 14 to 16 days (range, 10 to
- · Transmission occurs by person-to-person contact and by airborne secretions from the mouth, nose, and throat.
- · A live, attenuated vaccine was developed in Japan in 1974 and approved in the United States in 1995
- · Recent studies have suggested that immunity from the varicella vaccine may wane over time.

# **BACKGROUND: OUTBREAK**

- . The Minnesota Department of Health was notified of an school-based outbreak of varicella in November 2002.
- · Cases were identified in students attending a public elementary school in northern Minnesota
- 307 students were in attendance during the outbreak, including preschool, kindergarten, and grades one through five.

#### Table 1. Selected Demographics of Interviewed Students at Elementary School A at the Time of the Outbreak Students with Students without Varicella (n=55) Attack Rate<sup>a</sup>. % Varicella (n=194) Susceptibility Status Unvaccinated (n=36) Vaccinated (n=118) 25 Prior History (n=95) Preschool Kindergarter 29 29 29 31 30 30 25 24 36 Female -- no. (%) 31 (56) 105 (54) Time at School Median (hours/week) 18 - 49 10 - 58 Range a Attack Rate: students w/ varicella / (students w/ varicella + students w/o varicella)

- · Parents of students were interviewed by phone. The amended CDC varicella outbreak questionnaire included
- Demographic information
- Extracurricular activities
- Time spent at the school
- Medical history
- Illness history of students with outbreak-associated varicella
- Follow-up was conducted with clinics by verifying dates of immunization(s) and obtaining vaccine lot numbers, if available.


# CASE DEFINITON

- · Cases were defined by having an acute maculopapulovesicular rash with no apparent cause during the 6 months preceding the investigation.
- · Students were classified into three groups:
- Prior history of varicella illness
- Vaccinated, no prior varicella illness
- Unvaccinated, no prior varicella illness
- Severity was classified based on the number of lesions reported: 4,5,7
- <50 lesions was a mild case of varicella illness
- 50 to 500 lesions was a moderate case
- >500 lesions was a severe case

Table 2. Selected Risk Factors for Breakthrough Varicella among Vaccinated Students Students with Students without Relative Risk

Characteristic	Varicella (n=29)	Varicella (n=89)	(95% CI)	P Value
Age at Outbreak Onset				
Median (years)	7	7		0.31b
Range	5 - 11	4 - 11		
Vaccination Age				
12 to 15 Months	17	30	2.1 (1.1 - 4.1)	0.03ª
>15 Months	12	59		
Median (months)	15	20		0.04 <sup>b</sup>
Range	12 - 93	12 - 87		
Time since Varicella Va	accination			
5 years or more	21	38	2.6 (1.3 - 5.4)	<0.01a
4 years or less	8	51		
Median (years)	5	4		<0.01b
Range	2 - 7	0 - 7		
Asthma				
Yes	1	6	0.6 (0.1 - 3.6)	0.99a
No	28	83		
Chronic Ear Infections				
Yes	10	16	1.9 (1.0 - 3.5)	0.07a
No	19	73		
Other Lung Problems				
Yes	4	2	3.0 (1.5 - 5.8)	0.03a
No	25	9.7		

a Fisher's Exact Test and bWilcoxon Rank-Sum Test used for two-sided P values




## RESULTS

- 252 (82%) of 307 students were interviewed, three interviewed students were excluded since they received the varicella vaccine <12 months of age
- · 55 varicella cases occurred during the outbreak, which lasted from October 16 to December 5, 2002 (Table 1, Figure 1).
- · The varicella vaccine was 56% effective at preventing varicella entirely and 90% effective at preventing moderate varicella symptoms (calculations not
- · Length of time since varicella vaccination was associated with illness (Table 2, Figure 2).
- · Age at receiving the varicella immunization was identified as a risk factor for varicella illness (Table 2).
- · Time spent at school and extracurricular activities were not significant risk
- · No relationship between history of asthma and breakthrough varicella was identified (Table 2).
- · Receiving other vaccines within 30 days of the varicella vaccine was not identified as a risk factor for varicella illness
- · There were no patterns identified between varicella vaccine lot numbers and breakthrough varicella.
- · Vaccinated cases did present with a more mild form of the illness than unvaccinated cases (Table 3).

Figure 2. Length of Time Since Varicella Immunization, among Vaccinated

- Fewer lesions
- Less likely to have a fever
- Shorter duration of illness - Missed fewer days of school



Relative Risk Vaccinated Unvaccinated P Value Characteristic Students<sup>a</sup> (n=29) Students (n=20) (95% CI) 50 to 500 4.4 (2.2 - 9.1) <0.001 Less than 50 22 Parental Report on Illness Se 4.5 (2.0 - 10.2) <0.001b Moderate Mild 23 Lesion Location Entire body 2.4 (1.4 - 4.0) 0.0015 Torso/Head region 18 Duration of Illness Median (days) 0.029

Days of School Missed

Measured Temperature

Median (days)

Median (°C)

Range

Attack Rate (%

Range

Range

Fever

Yes

No

- Data on all characteristics missing for one student
- b Fisher's Exact Test and C Wilcoxon Rank-Sum Test used for two-sided P values

13

37.2 - 38.3

#### LIMITATIONS

· Interviews were conducted with parents, thus assessment of varicella illness was not validated by a physician

38.9

37.8 - 40

• Recall bias was possible since the outbreak investigation occurred 1-2 months following the last varicella case.

# **IMPLICATIONS**

- · First documented varicella outbreak in an elementary school setting with a vaccinated primary case.
- Breakthrough cases are still contagious
- School/Daycare exclusion recommended for breakthrough cases while ill
- · The varicella vaccine demonstrated a high degree of effectiveness against moderate varicella illness.
- · Breakthrough cases presented with a significantly milder form of varicella illness than unvaccinated cases

# DIRECTIONS FOR THE FUTURE

- · Further evaluation of varicella effectiveness and risk factors for breakthrough
- Continue to increase the national varicella immunization coverage level.
- Educating parents and physicians on the benefits of the varicella
- · Assess if administering a booster dose will offer additional protection.

## REFERENCES

- Centers for Disease Control. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996; 45:RR-11;1.
- Centers for Disease Control. Varicella-related deaths among children United States, 1997. MMWR Morb Mortal Wkly Rep 1998: 47:No 18:365-8.
- 3. Commmittee on Infectious Diseases, American Academy of Pediatrics. Recommendations for the use of live attenuated varicella vaccine. Pedatrics 1995; 95:791-6.
- 4. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a childcare center JAMA 1997: 278:1495-9 5. Galil K, Lee B, Strine T, et al. Outbreak of varicella at a day-care center despite vaccination. N Engl J
- Med 2002; 347:1909-15.

  6. Varis T. Vesikari T. Efficacy of high-titer live attenuated varicella vaccine in healthy young children. J
- Infect Dis 1996; 174(suppl3):S330-34 7. 7. Buchholz U. Moolenaar R. Peterson C. Mascola L. Varicella outbreaks after vaccine licensure: should they make you chicken? Pediatrics 1999: 104:561-3.